Author:
Ebogo-Belobo Jean Thierry,Kenmoe Sebastien,Mbongue Mikangue Chris Andre,Tchatchouang Serges,Robertine Lontuo-Fogang,Takuissu Guy Roussel,Ndzie Ondigui Juliette Laure,Bowo-Ngandji Arnol,Kenfack-Momo Raoul,Kengne-Ndé Cyprien,Mbaga Donatien Serge,Menkem Elisabeth Zeuko'o,Kame-Ngasse Ginette Irma,Magoudjou-Pekam Jeannette Nina,Kenfack-Zanguim Josiane,Esemu Seraphine Nkie,Tagnouokam-Ngoupo Paul Alain,Ndip Lucy,Njouom Richard
Abstract
BACKGROUND
Human immunodeficiency virus (HIV) is a major public health concern, particularly in Africa where HIV rates remain substantial. Pregnant women are at an increased risk of acquiring HIV, which has a significant impact on both maternal and child health.
AIM
To review summarizes HIV seroprevalence among pregnant women in Africa. It also identifies regional and clinical characteristics that contribute to study-specific estimates variation.
METHODS
The study included pregnant women from any African country or region, irrespective of their symptoms, and any study design conducted in any setting. Using electronic literature searches, articles published until February 2023 were reviewed. The quality of the included studies was evaluated. The DerSimonian and Laird random-effects model was applied to determine HIV pooled seroprevalence among pregnant women in Africa. Subgroup and sensitivity analyses were conducted to identify potential sources of heterogeneity. Heterogeneity was assessed with Cochran's Q test and I2 statistics, and publication bias was assessed with Egger's test.
RESULTS
A total of 248 studies conducted between 1984 and 2020 were included in the quantitative synthesis (meta-analysis). Out of the total studies, 146 (58.9%) had a low risk of bias and 102 (41.1%) had a moderate risk of bias. No HIV-positive pregnant women died in the included studies. The overall HIV seroprevalence in pregnant women was estimated to be 9.3% [95% confidence interval (CI): 8.3-10.3]. The subgroup analysis showed statistically significant heterogeneity across subgroups (P < 0.001), with the highest seroprevalence observed in Southern Africa (29.4%, 95%CI: 26.5-32.4) and the lowest seroprevalence observed in Northern Africa (0.7%, 95%CI: 0.3-1.3).
CONCLUSION
The review found that HIV seroprevalence among pregnant women in African countries remains significant, particularly in Southern African countries. This review can inform the development of targeted public health interventions to address high HIV seroprevalence in pregnant women in African countries.
Publisher
Baishideng Publishing Group Inc.
Reference288 articles.
1. WHO. WHO Guidelines Approved by the Guidelines Review Committee. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Geneva: World Health Organization. 2015. Available from: https://iris.who.int/bitstream/handle/10665/186275/9789241509565_eng.pdf?sequence=1
2. Strategies to increase couples HIV testing and counselling in sub‐Saharan Africa: a systematic review
3. Towards Universal Voluntary HIV Testing and Counselling: A Systematic Review and Meta-Analysis of Community-Based Approaches
4. Declines in HIV incidence among men and women in a South African population-based cohort
5. UNAIDS. Global HIV & AIDS statistics-Fact sheet. 2023. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf